Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001048477-24-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-29 | 2024-02-27 | BMRN | BIENAIME JEAN JACQUES | Dir | A - Grant | $0.00 | +143.6K | 563.2K | +34% | $0 |
| 2024-02-29 | 2024-02-27 | BMRN | BIENAIME JEAN JACQUES | Dir | S - Sale | $90.35 | -1,000 | 562.2K | -0.2% | -$90.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | A | A | 35,975 | $0.00 | 538,277 | D | — | — | (F1) Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. (F3) Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. (F4) Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. |
| 2 | Common | Common Stock | 2024-02-27 | A | A | 82,700 | $0.00 | 502,302 | D | — | — | (F1) Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. (F2) Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. (F3) Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. |
| 3 | Common | Common Stock | 2024-02-27 | A | A | 24,926 | $0.00 | 563,203 | D | — | — | (F1) Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. (F5) Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. (F3) Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. |
| 4 | Common | Common Stock | 2024-02-27 | S | D | 1,000 | $90.35 | 562,203 | D | — | — |